United Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- United Therapeutics reported 3rd quarter 2026 record total revenue of $833 million and record Tyvaso revenue of $504 million, with strong sequential growth and underlying demand.
- Management said Tyvaso growth was supported by increased starts, referrals, patient demand, dosing, and physician engagement, and reported more than 1,000 referrals for a UT product in October, the most ever in a single month.
- Management said Tyvaso DPI’s 80-microgram cartridge and higher dose kits helped more patients reach higher doses; about 1 in 3 patients who started Tyvaso DPI since their introduction had achieved these higher doses, twice the previous proportion.
- The company said a court decision upholding its intellectual property and its settlement with Liquidia provided clarity and reinforced the long-term durability of its base business; the settlement removed PHILD from the Eutrepia label and prohibited promotion or marketing for that indication and encouragement of off-label use.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2026 Corporate Update. My name is Krista, and I will be your conference operator today. All participants on the call portion of this webcast will be in a listen-only mode until the question-and-answer portion of this earnings call. If you would like to ask a question during that time, simply press star, then the number 1 on your telephone keypad. If you would like to withdraw your question, simply press star, one again. Please note that this call is being recorded. I will now turn the webcast over to Harry Silvers, Investor Relations at United Therapeutics.
Thank you, Krista. Good morning, everyone. It is my pleasure to welcome you to the United Therapeutics Corporation Third Quarter 2026 Corporate Update webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements. Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the products is available on our website.
Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer, Michael Benkowitz, our President and Chief Operating Officer, James Edgemond, our Chief Financial Officer and Treasurer, Dr. Leigh Peterson, our Executive Vice President of Product Development and Xenotransplantation, and Pat Poisson, our Executive Vice President of Strategic Development. Note that James Edgemond and I will participate in a fireside chat and one-on-one sessions at the UBS Global Biopharma Conference and Jefferies Global Healthcare Conference in London on November 16th and 17th, respectively. Additionally, members from our management team will participate in a fireside chat and one-on-one meetings at the 45th Annual J.P. Morgan Healthcare Conference in San Francisco in January of next year.
Our scientific, commercial, and medical affairs teams will be present at PHenomenal Hope 2026 on December 4th in Boston and at the Pulmonary Vascular Research Institute Annual Congress in Bangkok in late January of next year. I will turn the webcast over to Martine for an overview of our development pipeline and business activities.
Martine. Thank you, Harry, and good morning, everyone.
We have slides available for reference, and I encourage you to review those at your leisure. I am not going to speak directly to the slides. As we look back on the third quarter, I am incredibly proud of what our teams have accomplished. We executed at a high level across our business and across our company, delivering for patients while advancing one of the most ambitious growth strategies in biotechnology. The significance of this quarter extends beyond any individual result or milestone. It reflects the broader transformation underway at United Therapeutics as we build a comprehensive cardiopulmonary and respiratory medicine franchise capable of reaching dramatically more patients than ever before. For most of our history, UT has been known as a pulmonary hypertension company. Today, that legacy serves as the foundation for a much bigger UT.
Over the next several years, we expect to introduce wave after wave of innovation across multiple therapeutic and device platforms, from nebulized and dry powder therapies to soft mist inhalers, once-daily medicines, and combination products. We have 14 programs in development. Together, these advances are intended to address some of the largest unmet needs in pulmonary fibrosis and pulmonary hypertension. We are building an integrated portfolio designed around the needs of individual patients. Our strategy is to keep innovating so we can offer more patients the right therapy in the right format at the right time. The scale of that opportunity extends far beyond our historic pulmonary hypertension market. Across IPF, PPF, and PH-COPD alone, we are pursuing patient populations totaling approximately 1 million people in the United States. Supporting this strategy are significant and durable competitive advantages.
Our portfolio features extensive intellectual property protections, including fibrosis-related patents, device protections, and composition of matter protection for ralinepag, many of which extend into the 2040s. Just as important, our market advantages include decades of expertise, extensive engagement with physicians, specialized commercialization capabilities, manufacturing investments, and a proven ability to bring complex drug-device combinations to market. We are building on our strengths through the philosophy that has guided us for years: approve, then improve. We first establish a therapy as quickly as possible because our patients do not have time. Then, we continue to enhance convenience, administration, and treatment experience through new devices, formulations, and next-generation medicines. This disciplined approach creates a pipeline in which every new product builds on the foundation established by the last and provides improvements for the next.
As compelling as our cardiopulmonary and respiratory franchises are, they represent only one pillar of our long-term vision. In parallel, we continue to advance our manufactured organ alternatives programs and build the infrastructure we need to address one of medicine's greatest unmet needs. We believe this platform has the potential to revolutionize transplantation over the next decade, just as our therapies have revolutionized pulmonary hypertension over the past two decades. When I step back, I see a United Therapeutics stronger than at any point in our history, with a growing commercial business, late-stage assets of significant potential, multiple upcoming launches, and a clear strategy for creating value over the long term. In closing, thank you to our fellow Unitherians, patients, physicians, shareholders, and our other stakeholders for helping us fulfill our purpose.
And with that, I will turn the call over to our President, Michael Benkowitz, for an overview of our commercial performance for the quarter.
Mike? Thanks, Martine, and good morning, everybody.
For the third quarter of 2026, we delivered record total revenue of $833 million and record Tyvaso revenue of $504 million, highlighted by strong sequential growth and underlying demand. Three months ago, I said confidence is earned through execution, not projections. This quarter's results, our best quarter ever, demonstrate that execution and reinforce our conviction that our business has regained meaningful momentum. A huge shout-out to all of our commercial operations, and medical teams for their hard work, persistence, and performance. Tyvaso's performance was driven by strong underlying demand, as the patient metrics we highlighted last quarter translated into commercial results.
Starts, referrals, patient demand, increased dosing, and physician engagement all continue to support growth and emphasize the value of differentiated products, disciplined execution, a clear understanding of physician and patient needs, and our expertise and support in the field of pulmonary hypertension. Most importantly, we see meaningful room to grow from here. The investments we made earlier this year in resources and sharpening our messaging are working as intended by expanding our reach, deepening physician engagement, increasing disease awareness, and driving greater penetration across PAH and PH-ILD. We have greater conviction in our strategy than ever. Elsewhere, the recent court decision upholding our intellectual property, together with the settlement we reached, provide important clarity and reinforce the long-term durability of our base business.
The terms of our settlement were highly favorable for United Therapeutics, ultimately removing PH-ILD from the YUTREPIA label, preventing its promotion and marketing into that indication, and prohibiting Liquidia from encouraging off-label usage, which we will be monitoring very closely. With no direct branded competition on the horizon, we can remain focused on growing the large, under-penetrated PH-ILD market. Based upon the provisions contemplated in the settlement and damages structure, near-term expectations for transitions from YUTREPIA to Tyvaso should be moderate. The larger opportunity in PH-ILD continues to remain focused on expanding physician awareness, identifying more eligible patients, and growing new prescriptions. That gives Tyvaso a long runway for largely uncontested growth. Stepping back, our story is not about stabilizing our business. It is about building on renewed momentum from our durable commercial foundation, with two of the most important potential launches in our history still ahead.
Once approved, we expect nebulized Tyvaso in IPF and ralinepag in PAH will each address significant unmet need. Both are supported by compelling clinical data, and both have the potential to become multi-billion dollar growth drivers for United Therapeutics. These opportunities do not replace our current growth story, they accelerate it. In closing, our base business is performing, our commercial strategy is working, our competitive position is strong, and we expect to enter 2027 with substantially more momentum than we had entering 2026. To highlight this continued momentum, we received over 1,000 referrals for a UT product in October, the most ever received in a single month. We remain focused, accountable, and committed to continue delivering compelling results. As proud as we are of this quarter, we believe we are just beginning the full scale of what we are determined to achieve.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
